BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T. Clark to the company’s Board of Directors, effective today, August 1, 2025.
Mr. Clark served as Chief Executive Officer of Genentech and a member of the company’s Board of Directors from 2010 until his retirement in 2016. Under his leadership, Genentech launched 15 new drugs. Prior to serving as CEO, Mr. Clark held a number of senior management positions at Genentech. Before joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Sanofi S.A., Ivax Pharmaceuticals and G.D. Searle. Mr. Clark serves as a member of the boards of directors of Olema Oncology, Takeda Pharmaceutical Company Ltd., Kyverna Therapeutics, Inc., Corvus Pharmaceuticals, Inc. and Guardant Health, Inc. Mr. Clark previously served on the boards of Forty Seven Inc., Shire Pharmaceuticals, Inc., Avrobio, Inc. and Kite Pharma, Inc. Mr. Clark is currently an advisor to KKR & Co. Inc., and previously served on the board of the Biotechnology Industry Organization, as well as a member of the 12th District Economic Advisory Council of the Federal Reserve.
“We are very pleased to welcome Ian to our Board of Directors,” said Alexander Hardy, President and Chief Executive Officer of BioMarin. “Ian is a well-respected leader, who has been involved in the development and launch of numerous new therapies for patients with unmet needs. His experience over three decades as a biopharmaceutical industry executive and board director will bring valuable perspective, making him an ideal addition to our Board.”
“I am delighted to join BioMarin’s Board, as the company continues to advance important new medicines for people with genetically defined conditions,” said Mr. Clark. “I look forward to working with BioMarin to reach more patients around the world.”
